The diabetes combination drug Sidapvia can now be prescribed in general hospitals in Korea.

According to industry sources, AstraZeneca Korea's Sidapvia (dapagliflozin-sitagliptin), which is a combination of its SGLT-2 inhibitor ‘Forxiga’ and DPP-4 inhibitor ‘Januvia’, has passed the drug committees(DCs) of around 30 medical institutions in Korea, including tertiary hospitals such as Samsung Medical Center, Seoul National University Hospital, and Sinchon Severance Hospital.

As the company signed a copromotion agreement with HK Inno.N this year, what kind of synergy will be created through the partnership remains to be seen.

According to the Korean Diabetes Association's